Supernus Pharmaceuticals/SUPN

$29.75

0.85%
-
1D1W1MYTD1YMAX

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. It is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).

Ticker

SUPN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jack Khattar

Employees

612

Headquarters

Rockville, United States

SUPN Metrics

BasicAdvanced
$1.59B
Market cap
67.39
P/E ratio
$0.43
EPS
0.97
Beta
-
Dividend rate

What the Analysts think about SUPN

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
39.5% upside
High $45.00
Low $38.00
$29.75
Current price
$41.50
Average price target

SUPN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-10.33% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$153.8M
13.51%
Net income
$-15.9M
1,887.5%
Profit margin
-10.33%
1,650.85%

SUPN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 200%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.43
$0.70
$0.49
$0.24
-
Expected
$0.68
$0.17
$0.07
$0.08
$0.55
Surprise
-36.76%
311.76%
653.85%
200%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Supernus Pharmaceuticals stock

Buy or sell Supernus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing